EYPT - Eyepoint Pharmaceuticals Inc
Eyepoint Pharmaceuticals Inc Logo

EYPT - Eyepoint Pharmaceuticals Inc

https://eyepointpharma.com
Buy Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Range-Bound
As of 2025-09-10 (Snapshot)

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and markets ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company is headquartered in Watertown, Massachusetts.

52W High
$14.37
52W Low
$3.91
MA Status:
50D: Above 200D: Above
Beta (~1 neutral, <0.9 lower risk)
1.95
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-11.49
EV/Revenue (<3 favorable)
14.10
P/S (TTM) (<3 favorable)
18.61
P/B (<3 favorable)
3.93
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
3.51%
Institutions (25–75% balanced)
101.31%
Shares Outstanding
68,927,000
Float
42,619,900
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
51,898,000
Gross Profit (TTM)
-133,707,000
EPS (TTM)
-2.69
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
-11.67%
ROE (TTM) (>15% strong)
-0.74%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
-0.44
Momentum
Bearish momentum
Value
0.7152
Previous
0.5015
Trend
Rising
Signal Cross
No cross
As of
Sep. 05, 2025